Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medicare Legislation Elections

Part D Rebates Would Save $145Bn, CBO Says; Small Change Compared To ACA Repeal

  • Analysis

Executive Summary

Part D rebates remain a large potential savings for legislators if and when they look at Medicare reforms. But in the upcoming push to repeal the ACA, the $145bn potential savings from rebates looks almost trivial.

You may also be interested in...



Trump Makes A Nasty News Day For Pharma – But What Will It Really Mean?

President-elect threatens a government bidding process to control drug pricing in his first post-election press conference.

Trump’s Drug Pricing Remarks: A Gambit For Industry Self-Restraint?

Comments during recent interview shows president-elect continues to view drug pricing as populist issue, revives speculation he may take action to control prices.

Trump’s HHS, CMS Leadership Choices Underscore Focus On ACA Reform

Rep. Tom Price and health policy consultant Seema Verma will spearhead Trump Administration efforts to reform the Affordable Care Act as HHS secretary and administrator of CMS, respectively.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
Medicare Legislation Elections
Latest Headlines

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

Changes To EU Pharma Reform: More Questions Than Answers?

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

See All
UsernamePublicRestriction

Register

PS119739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By